Keryx Biopharmaceuticals, Inc. announced yesterday the pricing of its public offering of 5,030,000 shares of its common stock at an offering price of $14.05 per share. J.P. Morgan Securities Inc. is acting as the sole book-running manager in this offering with Bear, Stearns & Co. Inc. acting as co-lead manager, and Jefferies & Company, Inc., Oppenheimer & Co. Inc., Brean Murray & Co., Inc. and Punk, Ziegel & Company, L.P. are acting as co-managers. The offering is expected to close on July 20, 2005.

About Keryx:Headquarters: New York City

Lead compounds under Development:KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening disease caused by diabetes. KRX-101 is in Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. A

KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types.

More investor information here.